A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Brief summary (registry, in English)

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 225
• From 15 Jul 2025 to the primary completion date, 28 Feb 2027
• 88 sites in 7 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (88)

Sites in registry order. Pick your city on the disease page to sort them by distance.